The botulinum toxin market is projected to grow from US$ 7.38 billion in 2023 to US$ 19.03 billion by 2031, recording a CAGR of 12.6% during 2023–2031. The report includes growth prospects owing to the current botulinum toxin market trends and their foreseeable impact during the forecast period.

Botulinum toxins are neurotoxins produced by bacteria named Clostridium botulinum. After the toxin is injected into a muscle, it blocks nerve signals to the muscle, thereby blocking its contraction and resulting in a reduction in unwanted facial lines or features. Botulinum toxin injections such as Botox and Dysport improve the appearance by relaxing the muscles that cause wrinkles. These injections also treat migraines, hyperhidrosis, overactive bladder, and eye problems. The botulinum toxin market size is likely to surge by 2031 owing to significant growth opportunities presented by developing countries.

Growth Drivers:

Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics Drives Botulinum Toxin Market

Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, botulinum toxin type A-based (BoNTA) facial cosmetic treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Moreover, a total of 2.5 million minimally invasive cosmetic procedures involving botulinum toxin were performed in the US in 2020. Thus, an upsurge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.

Nonsurgical Procedures, by Country, 2021

Source: The International Society of Aesthetic Plastic Surgery (ISAPS), 2021

Although botulinum treatment is approved worldwide to treat eyelid and throat spasms, reduce facial wrinkles, and control excessive sweating, the toxin may cause serious side effects that can be life-threatening. Common side effects of botulinum toxin treatments are mentioned below.

• Patients face problems in speaking, swallowing, or breathing due to the weakening of associated muscles. These side effects can be severe and result in mortality.
• Spread of botulinum toxin to body areas other than the injection site causes severe symptoms. These ill effects include the loss of strength and muscle weakness, blurred vision, double vision, drooping eyelids, trouble saying words clearly, hoarseness or change or loss of voice, loss of bladder control, trouble swallowing, and difficulty breathing.
• Other side-effects of botulinum toxin include upper respiratory tract infection. Children receiving botulinum treatment for urinary incontinence may experience urinary tract infections and bacteria in the urine. Other side effects in adults treated for urinary incontinence include painful urination, apart from urinary tract infections.

Botox has a boxed warning. A boxed warning is an official alert from the Food and Drug Administration (FDA) regarding potentially harmful side effects of a medication. Spreading of Botox outside of the injection site may result in symptoms identical to those of botulism. Further, headache or flu-like symptoms, crooked smile, and dry eyes are the other major side effects of botulinum toxin. Such harmful side effects limit the adoption of botulinum toxin treatment, thereby hampering the botulinum toxin market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Botulinum Toxin Market: Strategic Insights

Market Size Value in	US$ 5,307.71 Million in 2021
Market Size Value by	US$ 8,977.62 Million by 2028
Growth rate	CAGR of 7.8% from 2021 to 2028
Forecast Period	2021-2028
Base Year	2021

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The botulinum toxin market analysis is performed by considering the following segments: product, application, and end user.

Segmental Analysis:

By product, the botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger botulinum toxin market share in 2023. It is anticipated to register a higher CAGR of 12.7% during 2023–2031. Botulinum toxin type A is a purified form that has a wide range of applications and a favorable safety profile. It is used to block the release of acetylcholine in the treatment of chronic sialorrhea, spasticity, and dystonia, as well as in various cosmetic applications.

By application, the botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger market share in 2023, and it is anticipated to register a higher CAGR of 13.3% during 2023–2031. The market for the medical segment is further categorized into chronic migraine, muscle spasm, overreactive bladder, hyperhidrosis, and others. Also, the market for the aesthetic segment is subsegmented into frown lines/glabellar, forehead lines, crow’s feet, square jaw/masseter, and others. Botulinum toxin is a neurotoxin used to treat and manage various medical conditions, including chronic migraine, spastic disorders, cervical dystonia, and detrusor hyperactivity. Medical applications of botulinum toxin include chronic migraine, muscle spasms, overreactive bladder, and hyperhidrosis.

The botulinum toxin market, by end user, is segmented into specialty and dermatology clinics, hospitals and clinics, and others. The specialty and dermatology clinics segment held the largest market share in 2023. It is anticipated to register the highest CAGR of 13.4% during the forecast period.

Regional Analysis:

The scope of the botulinum toxin market report includes North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2023, North America accounted for the largest botulinum toxin market share. Market growth in this region is driven by increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow's feet by the FDA-approved botulinum toxin treatment methods for cosmetic indications and horizontal forehead wrinkles provide predictable results, alongside exhibiting fewer side effects and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18–65.

Europe occupies a significant position in the global botulinum toxin market, and it is expected to record a strong growth rate during the forecast period. The market growth in the region is mainly attributed to product developments by botulinum toxin companies and an upsurge in the awareness of modern beauty standards among people from all age groups in European countries such as Germany, the UK, France, and Italy. In addition, advancements in healthcare systems are likely to propel the demand for botulinum toxin across the region in the coming years.

Botulinum Toxin Market Report Scope

Competitive Landscape and Key Companies:

The botulinum toxin market forecast can help stakeholders in this marketplace plan their growth strategies. AbbVie Inc., Merz Pharma, Medytox, Ipsen Pharma, Galderma, Revance Therapeutics Inc., Lanzhou Institute of Biological Products Co Ltd, Evolus Inc, Hugel Inc, and Aquavit are among the prominent companies profiled in the botulinum toxin market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide. As per company press releases, below are a few recent developments:

• In January 2024, Medytox, Inc. announced the formation of Luvantas, Inc. as its wholly owned North American subsidiary. Luvantas is a new medical aesthetics company committed to bringing innovative solutions to the North American market. It is working with Medytox to seek approval for its upcoming NivobotulinumtoxinA to introduce it into the US and Canada.
• In March 2024, Hugel, a medical aesthetics company, received US FDA approval for Letybo injection (letibotulinumtoxinA-wlbg) for the treatment of Glabellar Lines.
• In October 2022, Hugel resubmitted the Biologics License Application (BLA) to the US FDA for its botulinum toxin called Botulax for the treatment of glabellar lines. Hugel received a Complete Response Letter (CRL) from the US FDA in March 2022 after submitting the BLA for Botulax (50 and 100 units) to advance into the US market. The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the US FDA. After the approval, Hugel entered into the US market in the first half of 2023.
• In February 2022, Merz Therapeutics invested up to US$ 3 million to expand its strategic partnership with Vensica Therapeutics, Israel. This investment followed the strategic license and collaboration agreement signed in 2021. Merz thus executed its contractual agreement to participate in Vensica’s Series C financing round and invest in the start-up.